Results indicated that 7 out of 9 study subjects reported significant pain reduction (defined as 50% or greater) observed for up to 12 months of evaluation. The study demonstrated no safety issues over the treatment period. Study subjects reported an average pain score reduction of 6 to 1 (an 83% pain reduction) based on a 0 to 10 Numerical Rating Scale. Significant pain reduction was reported in 91% of all treatment sessions. In addition, more than half of the subjects discontinued their narcotic pain medication use during the study.

The study was led by Dr. Amol Soin of the Kettering Health Network Innovation Center and the Ohio Pain Clinic. “It’s outstanding to see the Neuros technology continue to provide such significant pain relief for patients,” said Dr. Soin. “It’s also very promising to see the safety results confirmed over a larger set of patients for such an extended period of time,” he added.

Jon J. Snyder, President and CEO of Neuros Medical, said, “We are extremely pleased with the opportunity to improve the lives of amputees. Our study results have shown that study subject pain scores are consistently and significantly reduced over this long term evaluation. This provides further clinical evidence of the strong potential of our treatment for patients suffering from chronic pain. We look forward to sharing more details at the upcoming International Neuromodulation Society’s 11th World Congress in Berlin, Germany, June 8-13.”

* * *

About Neuros Medical, Inc. Neuros Medical, a Cleveland, Ohio based neuromodulation company, is focused on developing proprietary therapies for unmet needs to patients worldwide. The Company’s patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of conditions including amputation pain, post-surgical pain, migraine, and trigeminal neuralgia.

Durham, N.C. – May 29, 2013 – Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the transmission of a live satellite feed of a clinical case using the new Tryton Side Branch SHORT Stent to an audience of several hundred interventional cardiologists at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.

The live procedure was performed May 22 from the Erasmus Medical Center in Rotterdam, the Netherlands by Nicolas Van Mieghem, M.D. “This case was a real-world example of the benefits a dedicated bifurcated stent can offer in daily practice when treating a challenging lesion,” said Maceij Lesiak, M.D., co-chairman of the session on “Complex Bifurcation Stenting”.

“The live case reinforced that the Tryton Side Branch Stent enables physicians to treat complex bifurcated coronary disease in a straightforward manner,” said Shawn P. McCarthy, president and CEO of Tryton Medical. “Panelists commented that Dr. Van Mieghem maintained total control treating the complex bifurcation and achieved a successful outcome.”

McCarthy continued, “This was a tremendous EuroPCR for Tryton Medical. The new Tryton Side Branch SHORT Stent was well-received by physicians, award-winning data was presented supporting Tryton’s dedicated bifurcation stenting as a treatment strategy, we held a world-class symposium featuring new data on use of the Tryton Stent for left main disease, and we capped the week announcing our participation in the prestigious Nordic-Baltic Dedicated Bifurcation Trial.”

Presentations confirmed consistent clinical results with the Tryton Side Branch Stent:

• A clinical symposium featured a comprehensive overview of Tryton Side Branch Stent clinical evidence, chaired by leading physicians Martin B. Leon M.D. and Patrick W. Serruys M.D. At the symposium, Antonio Bartorelli, M.D. of Centro Cardiologico Monzino in Italy, highlighted the Tryton IDE study as a landmark study in the treatment of coronary bifurcation disease and anticipated the outcomes of this study to be presented at TCT later this year.

• Jens F. Lassen, M.D. of Aarhus University Hospital in Skejby, Denmark announced, on behalf of the Nordic-Baltic Bifurcation Study Group, the Nordic-Baltic Dedicated Bifurcation Trial comparing use of final kissing balloon compared to no final kissing balloon in a prospective, controlled, randomized, multicenter clinical trial. In addition, he noted that the Tryton Side Branch Stent is the latest evolutionary step in the treatment of bifurcation disease.

• Robert-Jans van Geuns, M.D. of Erasmus Medical Center in Rotterdam, the Netherlands presented the one month clinical follow-up data of 30 patients in the prospective clinical ‘first in human’ registry treating patients with left main disease. “Excellent acute gain and angiographic results in three segments of the bifurcation is obtained,” concluded Dr. van Geuns. He added, “the newly CE-marked Tryton Side Branch SHORT Stent will broaden the treatment options in patients with a short main branch landing zone.”

• A clinical case using a Tryton Side Branch Stent was awarded the “Best Clinical Case of EuroPCR 2013″. The award was presented on May 24 in main arena for work by Joanna Wykrzykowska, M.D. on the topic of “Successful treatment of a complex bifurcation lesion with extensive side branch involvement with bioresorbable vascular scaffolds in combination with a dedicated bifurcation side branch stent: evaluation and new insights with 3D-OCT”.

The Tryton Side Branch Stent is supported by robust clinical evidence in more than 1,000 patients. Published data in a patient pooled analysis from more than 900 patients treated with the Tryton Side Branch Stent in more than 8 European post-marketing registries demonstrated low target lesion revascularization rates of 2.9 percent at six months and 4.0 percent at one year, and a low 0.5 percent thrombosis rate at one year. More than 7,500 patients have been treated with the Tryton Side Branch Stent and it is commercially available throughout Europe, Russia and the Middle East. The new Tryton Side Branch SHORT Stent enables physicians to broaden treatment options in bifurcations in large vessels with a short main branch landing zone.

Tryton has completed enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent. The company anticipates study outcomes will be presented at TCT 2013 in San Francisco.

About Coronary Bifurcation Disease

Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary

tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions. The Tryton Side Branch Stent has not been studied extensively in left main disease.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole of Spray Venture Partners to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3×5 Special Opportunity Fund. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.

# #

The announcement was made today in Paris at EuroPCR 2013, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions.

“The use of a dedicated bifurcation stent, such as the Tryton Side Branch Stent, is a natural evolution for the Nordic-Baltic Bifurcation Study Group,” said Jens F. Lassen, M.D., of the Department of Cardiology, Aarhus University Hospital, Skejby and principal investigator for the study. “The trial will examine if we can maintain the superb results reported thus far in the literature with the Tryton Stent utilizing a streamlined treatment protocol. Additionally, the Study Group looks forward to utilizing OCT to better characterize complex bifurcation treatment strategies.”

The Nordic-Baltic Dedicated Bifurcation Trial is the latest investigation from the Study Group, which has a history of examining different techniques for treating bifurcation lesions in the Nordic I, II, III and IV studies. The publications associated with these studies are among the most frequently cited by interventional cardiologists.

“Tryton Medical is honored the prestigious Nordic-Baltic Bifurcation Study Group has chosen to examine the market-leading Tryton Side Branch Stent in this trial,” said Shawn McCarthy, CEO of Tryton Medical. “We are a company committed to investing in evidence-based care as demonstrated in our extensive real-world global registries, our randomized U.S. pivotal study, and, now, with these world-class investigators studying the optimization of the Tryton Stent in bifurcations.”

The Tryton Side Branch Stent is supported by robust clinical evidence in more than 1,000 patients. Published data in a patient pooled analysis from more than 900 patients treated with the Tryton Side Branch Stent in more than 8 European post-marketing registries demonstrated

low target lesion revascularization rates of 2.9 percent at six months and 4.0 percent at one year, and a low 0.5 percent thrombosis rate at one year. More than 7,500 patients have been treated with the Tryton Side Branch Stent and it is commercially available throughout Europe, Russia and the Middle East. The Tryton Side Branch SHORT Stent was introduced this week at EuroPCR, enabling physicians to broaden treatment options in bifurcations in large vessels with a short main branch landing zone.

The Tryton Side Branch Stent is an investigational device in the United States. Tryton has completed enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent and anticipates study outcomes will be presented at TCT 2013 in San Francisco.

About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions. The Tryton Side Branch Stent has not been studied extensively in left main disease.

About the Tryton Side Branch Stent System
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole of Spray Venture Partners to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3×5 Special Opportunity Fund. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.

Durham, N.C. – May 16, 2013 – Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the company received the CE Mark for the Tryton Side Branch SHORT Stent, a novel coronary stent system that broadens the treatment options in bifurcations in large vessels with a short main branch landing zone. The Tryton Side Branch SHORT Stent length is 15 mm, or 3mm shorter in the main branch zone than the standard Tryton Side Branch Stent. The company is launching the product immediately in CE Mark countries. This innovation leverages the company’s proprietary, first-in-class Tri-ZONE® technology and adds to the Tryton family of stents.

Joanna J. Wykrzykowska, M.D., Ph.D., from the Academic Medical Center, University of Amsterdam, Netherlands completed the first implant of the Tryton Side Branch SHORT Stent. “The Tryton Side Branch SHORT Stent is an important advance in coronary stents. It gives me the control I need to treat patients who present with significant disease in a large, bifurcated vessel and whose anatomy in the main branch makes it challenging to deliver a longer size stent, ” said Dr. Wykrzykowska.

Dr. Wykrzykowska continued, “The Tryton Side Branch SHORT Stent may be particularly helpful when treating disease in the left main artery. Left main coronary artery disease has historically been challenging to address interventionally, but this new stent provides confidence I can deliver it where it needs to go and ensure both the main branch and side branch openings receive optimum scaffolding and support.”

The company will launch the Tryton Side Branch SHORT Stent during EuroPCR 2013 in Paris at their exhibitor booth #M27.

“Interventional cardiologists told us they would value a dedicated bifurcation stent designed to work in their more challenging patients. The Tryton Side Branch SHORT Stent was developed in response to this request,” said Shawn McCarthy, CEO of Tryton Medical. “We are pleased we were able to quickly and effectively iterate our stent design, secure regulatory approval and bring doctors the confidence and control they expect from Tryton, optimized for more complex bifurcations.”

###

The Tryton Side Branch SHORT Stent is supported by the robust clinical evidence of the Tryton Side Branch Stent. Published data from more than 1,000 patients treated with the Tryton Side Branch Stent in more than 8 European post-marketing registries demonstrated low target lesion revascularization rates of 2.9 percent at six months and 4.0 percent at one year, and a low 0.5 percent thrombosis rate at one year. More than 7,500 patients have been treated with the Tryton Side Branch Stent and it is commercially available throughout Europe, Russia and the Middle East.

The Tryton Side Branch Stent is an investigational device in the United States. Tryton has completed enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent and anticipates study outcomes will be presented at TCT 2013 in San Francisco.

About Coronary Bifurcation Disease

Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions. The Tryton Side Branch Stent has not been studied extensively in left main disease.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole of Spray Venture Partners to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3×5 Special Opportunity Fund. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.

Keller brings with him more than 20 years of experience in drug discovery and development, including scientific leadership roles at Pfizer, Pharmacia, Monsanto/Searle and Hoffman-LaRoche, and most recently, as Global Product Manager with Sigma-Aldrich. As a 2009-10 Innovation Acceleration Partnership Fellow at Washington University in St. Louis, Keller participated in a National Science Foundation training program in entrepreneurship and commercialization of science and technology.

In addition to his position as a RiverVest Entrepreneur-in-Residence, Keller serves as V.P., Research at Lumena Pharmaceuticals, Inc. in San Diego, CA, a role which currently requires most of his time. Lumena is a RiverVest portfolio company developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically improve patient health.

As Entrepreneur-in-Residence, Keller will work with the RiverVest team to identify and evaluate potential funding opportunities in the pharmaceutical and biotechnology space. “We are excited to have Brad on the team,” says John McKearn, RiverVest Managing Director. “He has the perfect set of skills and experience to help us, particularly as we selectively found promising life science companies with the intention of building and selling them within five years.”

Keller has a Ph.D. in Biochemistry from the University of Kansas and a B.A. in Biology and Chemistry from the University of Delaware. He also completed post-doctoral studies in Pharmaceutical Chemistry at the University of Kansas.

 SAN DIEGO – May 8, 2013 – Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the company has secured $23 million in Series A financing. Investors include Pappas Ventures, RiverVest Venture Partners and Alta Partners. Founded in 2011 by Pappas Ventures, Lumena will primarily use the funding to advance the clinical development of LUM001, the company’s lead product candidate for the treatment of cholestatic liver disease in pediatric and adult patients.

LUM001 is being developed as a possible therapy for progressive liver damage and debilitating symptoms associated with a number of liver conditions that result in impaired bile acid flow and retention of bile acids in the liver, leading to progressive liver damage and, ultimately, liver failure.

Cholestatic liver diseases are characterized by elevated bile acids and intractable itch, which is generally the most debilitating symptom afflicting adults and children with these diseases. Treatment with anti-pruritics typically provides only modest relief, and other available drug treatments are of limited value. Surgical procedures that divert bile from recirculation can lower serum bile acids, reduce itch and improve liver function in some patients. LUM001 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), which recycles intestinal bile acids back into the circulation. By reducing serum bile acids without surgery, LUM001 may be of value in the treatment of cholestatic liver diseases.

“There is an urgent need for effective pharmacological treatments for patients with cholestatic liver disease who experience itching so extreme that it causes severe sleep disruption and scratching with skin destruction and scarring — symptoms which significantly impair quality of life,” said Mike Grey, president and CEO of Lumena Pharmaceuticals. “Lumena’s targeted approach to inhibiting bile acid recirculation to the liver with LUM001 may improve liver function, relieve symptoms and dramatically impact patient health without the need for risky surgeries that reduce bile acids.”

In association with the financing, the following were named to Lumena’s board of directors: David R. Savello, Ph.D., Scientific Advisory Board, Pappas Ventures; John McKearn, Ph.D., managing director, RiverVest Venture Partners; and Robert Alexander, Ph.D., executive chairman, ZS Pharma and formerly a general partner at Alta Partners.

The company has recruited the following management team:

Mike Grey, president, CEO and co-founder, is a venture partner with Pappas Ventures and was previously CEO of SGX Pharmaceuticals, which was acquired by Eli Lilly & Co. in 2008.

Alejandro Dorenbaum, M.D., chief medical officer, previously of Genentech and BioMarin, has extensive experience in developing drugs for orphan indications.

Ciara Kennedy, Ph.D., vice president, operations, joined Lumena from Cypress Bioscience Inc. where she played a key role in the company’s FDA approval of Savella® for fibromyalgia, two corporate acquisitions and the in-licensing of several clinical assets.

Bradley T. Keller, Ph.D., vice president, research, is an experienced drug discovery scientist who was previously responsible for the LUM001 program at Searle/Pharmacia.

Alana B. McNulty, chief financial officer, joins in a consulting capacity, bringing more than 20 years of experience working with biotechnology companies in various senior finance, business development and operating roles.

Slava Gedulin, M.D., Ph.D., vice president, pharmacology, brings drug development experience from Amylin, where her extensive research was instrumental in bringing SYMLIN® and BYETTA® to market.

“Lumena’s team has the vital experience necessary to successfully execute the clinical development of LUM001, including leadership in obtaining multiple drug approvals, expertise in pediatric drug development for orphan indications, as well as deep knowledge of this target for drug development,” said John McKearn, managing director, RiverVest Venture Partners. “LUM001 could dramatically impact patient health for a population in desperate need of more effective treatment options, and we are glad to be a part of this potentially game-changing company.”

Lumena licensed LUM001 from Pfizer where it was originally evaluated at its Pharmacia legacy company as a cholesterol lowering drug. It has been extensively studied in 12 clinical trials in more than 1,400 subjects and is therefore positioned for rapid progress through late phase clinical development. Clinical studies have demonstrated that LUM001 can reduce serum bile acid levels and may be effective in managing symptoms in many patients with cholestatic liver disease. Lumena plans to initiate a Phase II study of LUM001 in adults with Primary Biliary Cirrhosis (PBC), a rare chronic disease that presents with inflammation and damage of the bile ducts in the liver. The company also plans to initiate Phase II studies of LUM001 in children with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), rare congenital disorders that also present with cholestatic liver disease.

Lumena also licensed the patent rights and a package of clinical and non-clinical data from Sanofi for LUM002, a highly potent, selective inhibitor of ASBT. LUM002 was previously in phase 1 development by Sanofi as a cholesterol lowering drug. Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this year as a first step in launching the development program for this compound.

LANGHORNE, PA, April 29, 2013 – St. Mary Medical Center in Langhorne, PA, in partnership with Centerre Healthcare Corporation, headquartered in Nashville, TN, today announced plans for a newly designed acute rehabilitation hospital, the first specialty hospital of its kind in Bucks County. Scheduled for completion in the spring of 2014, the St. Mary Rehabilitation Hospital will provide acute inpatient rehabilitation services for patients who require a high level of specialized treatment. Dedicated brain-injury, spinal-cord-injury, trauma and stroke units will help promote the recovery of individuals who have functional deficits resulting from injury or illness.

St. Mary finalized the purchase of property that was the site of the former Neshaminy Middle School from the Neshaminy School District to develop the St. Mary Rehabilitation Hospital and Outpatient Campus. The St. Mary Rehabilitation Hospital is part of the first phase in the development of this new campus, which will be located directly across the street from the Medical Center’s main campus. With the opening of the new 50-bed rehabilitation hospital, St. Mary will relocate its existing 31-bed rehabilitation unit currently on the main campus, and convert the medical center space to a private-bed patient-care unit.

The new state-of-the-art 55,000 square foot specialty hospital will provide attractive patient-friendly private rooms. Physical, occupational and speech therapy, and neuropsychology are among services provided to help patients regain their highest level of functional independence. The hospital will include spacious therapy gyms equipped with the latest in rehabilitative equipment, indoor and outdoor dining areas, simulated home training environments and an innovative outdoor therapy courtyard complete with a putting green, basketball court and walking path.

“A free-standing hospital dedicated to rehabilitation represents a unique investment in caring for the needs of the community. Our inpatient rehabilitation is renowned for its excellence in rehabilitative care, and we believe a dedicated hospital expands our rehabilitation services to meet those needs,” says Greg Wozniak, St. Mary President and CEO.

Unique to this region will be a self-contained, secured Brain Injury Unit to treat patients with behavioral and cognitive issues that may put them at-risk in a less structured environment. The secure Brain Injury Unit will have a supervised, low stimulation, calm setting with focused therapies to assist these patients in recovery.

“We are pleased to be joining St. Mary Medical Center in being able to bring this level of specialized care to this community”, said Pat Foster, CEO of Centerre Healthcare. “We partner with top acute-care hospitals across the United States with the common goal of providing exceptional rehabilitation services and uniquely designed facilities to best serve the needs of patients in their own community.”

St. Mary chose to partner with Centerre based on its nationally renowned reputation and experience in providing high-quality, patient-centered care and rehabilitation services focused on improving clinical outcomes.

The need for physical rehabilitation services is anticipated to grow as the population ages in our region and continues to be affected by the high incidence of stroke, cardiovascular and orthopedic conditions. In addition, the specialty hospital will complement the services of the St. Mary Regional Trauma Center in continuing the rehabilitation needs of patients who have suffered serious injury.

This hospital will prove a valuable resource for our community, fulfilling a unique need for specialized rehab care,” says Dr. Guillermo Bernal, Co-Medical Director of the Inpatient Rehabilitation Unit at St. Mary. “People will welcome not having to travel to Center City for this level of advanced clinical care.”

“We are focused on quality outcomes for our patients,” says Lisa Haney, Executive Director of Inpatient Rehabilitation at St. Mary. “Our clinical team works hard to ensure our patients make the most progress possible and return to their home environment as quickly as possible.” In 2012, the rehabilitation unit at St. Mary ranked in the top 5 percent of 789 nationwide rehabilitation facilities evaluated by the UDSMR® in their Program Evaluation Model.

A specialized hospital dedicated solely to physical rehabilitation is beneficial to patient recovery. “The interdisciplinary rehab team, including doctors, therapists, nurses and aides, work together to ensure the highest quality outcomes for our patients,” says Co-Medical Director of the Inpatient Rehabilitation Unit at St. Mary, Dr. William Bonner. “The clinical team works closely with each patient and their caregivers to create a treatment program to meet individualized goals and return the patient as close to their previous level of function as possible”.

With the addition of a specialized hospital for inpatient rehabilitation, St. Mary strengthens the level of comprehensive care offered to meet the challenging needs of often complex medical conditions. Most patients who have been in hospital-based rehabilitation benefit in continuing therapy to maintain and improve overall health and functional ability. Outpatient rehabilitation services are provided on the hospital main campus and at the Cornerstone Executive Suites near Oxford Valley Mall. The experienced certified therapists at St. Mary integrate evidence-based treatments, leading-edge technologies and adaptive techniques to promote recovery. In addition, patients can continue to improve mobility, strength and endurance with step-down programs available through the Wellness Center on the main hospital campus.

April 16, 2013, San Diego, CA – Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to assess whether a patient may be at greater risk for both bleeding or ischemic events, as an aid to manage therapeutic treatment decisions and accurately assess the antiplatelet effect from P2Y12 inhibitors (such as clopidogrel, prasugrel and ticagrelor).

The expanded claim was developed based on the ADAPT-DES registry (8500 patients using the VerifyNow system), which validated the existence of a therapeutic window. The data demonstrated that patients with a P2Y12 Reaction Units (PRU) result of ≥208 were at a significantly increased risk of cardiovascular events and patients with a PRU of <95 were receiving virtually no additional protection from cardiovascular events, but at a significantly increased risk of bleeding.

“Balancing efficacy and safety is one of the most critical choices we need to make when selecting a P2Y12 inhibitor for long term use in our patients” said Dr. Gilles Montalescot, MD, PhD, Professor of Cardiology for the Institut de Cardiologie at Hospital la Pitié-Salpêtrière in Paris, France. “In the ARCTIC study, we saw signs that a platelet reactivity guided strategy may result in less bleeding. This association was found in ADAPT-DES and suggests that we can use the information provided by the test to assess the bleeding risk of patients on treatment. ”

Previous studies have demonstrated the association between PRU and increased risk for recurrent ischemic and bleeding events. However, most of those studies were too small to warrant a label change for the VerifyNow P2Y12 Test. With the large number of patients, and real-world patient population represented in ADAPT-DES, there was significant evidence to proceed with a CE marked claim.

“Most prior analyses have focused upon platelet hyporesponsiveness as an established correlate of adverse ischemic events such as stent thrombosis,” stated Dr. Ajay J. Kirtane, MD, SM, Chief Academic Officer of the Center for Interventional Vascular Therapy at Columbia University Medical Center / NewYork-Presbyterian Hospital in New York City, who presented these data at ACC.13. “In this analysis from ADAPT-DES, the demonstration of increased bleeding events at the lowest levels of on-treatment platelet reactivity – independent of other baseline characteristics – suggests that there may be a price to pay for over-aggressive platelet inhibition, which can be measured through a point-of-care assay.”

The addition of the therapeutic window claim marks the second major change to the intended use of the CE Marked VerifyNow P2Y12 Test in the last two years. With a similar claim currently being reviewed by the FDA, Accumetrics is on track to have the first platelet reactivity test with a claim in the U.S. and the EU to assess risk of both bleeding and ischemic events.

“The achievement of this new CE marked claim is a very positive step forward for the VerifyNow System and the entire field of platelet reactivity testing,” said Timothy Still, President and CEO of Accumetrics. “The expanded claims will provide greater clarity on how to interpret the VerifyNow P2Y12 and PRU Test results, which will enable an improved quality of care for the millions of patients on antiplatelet therapies.”

The VerifyNow System is currently used in over 1000 facilities in the United States and over 80 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke. Platelet reactivity testing is already included in the following guidelines; European Society of Cardiology NSTE-ACS, ACC/AHA UA/NSTEMI, ACC/AHA/SCAI PCI and Society of Thoracic Surgeons Use of Antiplatelet Drug in Patients Having Cardiac and Non-Cardiac Surgery.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. clopidogrel) and GP IIb/IIIa inhibitors, the VerifyNow System provides valuable information to help physicians make informed clinical decisions. The VerifyNow P2Y12 Test and the VerifyNow PRUTest are whole blood assays used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade. Additionally, the VerifyNow P2Y12 Test is indicated outside the US for evaluating the risk of bleeding and the risk of recurrent ischemic events in cardiovascular patients.

For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc.

# # #

CONTACTS:

Jakob Jakobsen
310-309-1003 (Office)
310-409-5351 (Cell)

Timothy I. Still
President and CEO
Accumetrics
858-404-8260

The $28 million, 63,000 square foot facility will have 60 beds and provide inpatient rehabilitation for patients who are recovering from strokes, brain or spinal cord injuries, amputations, complex orthopedic injuries and other conditions. Construction is estimated to take about a year.

Currently, rehabilitation services are offered at Mercy Hospital Springfield. As a Level I trauma center for Arkansas and Missouri, as well as the region’s only burn unit, the need for rehabilitation has outgrown the 35 beds available in the current space. “This new facility will give us the room we need and lift the spirits of our patients,” explained Dr. Hollis Bell, medical director for rehabilitation at Mercy Hospital Springfield. “So many can’t wait to get out of the hospital, and while this will still be an inpatient facility, it will give patients a real sense that they are making progress, and inspire them to continue the tough work ahead.”

Mercy Rehabilitation Hospital Springfield will challenge patients to tackle obstacles they will encounter in everyday life. “Little things like walking on gravel may not seem like a big deal to most of us,” said Dr. Robert W. Steele, president of Mercy Hospital Springfield. “But after a traumatic injury, learning how to navigate various surfaces is a major milestone. We’ll have features that will allow patients to practice that in a safe environment.”

Other unique features will include:

• Apartment where patients and families can practice daily living tasks
• Gymnasiums featuring high-tech therapy devices and treatments
• Dedicated rooms for burn patients
• Brain injury unit with monitored rooms, specialized beds, patient lifts and dedicated therapy space and dining area
• Dedicated stroke unit with specialized equipment
• Specially-equipped rooms for bariatric patients
• Private, family-friendly rooms with sleeper chairs
• Pet therapy and recreation programs

Mercy Rehabilitation Hospital Springfield is a partnership between Mercy and Centerre Healthcare Corporation, a national leader in the development and operation of rehabilitation hospitals. Centerre has partnered with Mercy for similar projects in St. Louis and Oklahoma City. McCarthy Building Companies, Inc. is the construction manager.

Mercy Springfield Communities is comprised of Mercy Hospital Springfield, an 866-bed referral center; five regional hospitals in Lebanon, Aurora, Cassville, Mountain View, and Berryville, Ark.; Mercy Clinic, a 500-plus physician clinic with 70 locations throughout the region. It is part of Mercy, which is the sixth largest Catholic health care system in the U.S. and serves more than 3 million people annually. Mercy includes 32 hospitals, 300 outpatient facilities, 38,000 co-workers and 1,900 integrated physicians in Arkansas, Kansas, Missouri and Oklahoma. Mercy also has outreach ministries in Louisiana, Mississippi and Texas. For more about Mercy, visit www.mercy.net.

Centerre Healthcare Corporation – is a national provider of inpatient acute rehabilitation services, dedicated solely to partnering with medical centers to complement their healthcare continuum through joint development and operation of acute rehabilitation hospitals and units. Modern Healthcare named Centerre as the fastest growing hospital company in the United States in 2012. Centerre Healthcare facilities rank among the top inpatient rehabilitation facilities (IRFs) in the IRF database of Uniform Data System for Medical Rehabilitation (UDSMR); a ranking which provides a measure of the company’s quality clinical outcomes. Centerre has been named in the annual ranking of the 5,000 fastest-growing private companies in America by Inc. magazine. For more about Centerre, visit www.centerrehc.com.

Contact:
Sonya Kullmann
Mercy Springfield Communities
417-343-7610
sonya.kullmann@mercy.net

Michele Niec
Centerre Healthcare
615-516-2771
michele@commelements.com

O’Donnell joins a panel of commercial, financial and technical experts advising Bioscience Catalyst and its tenants on all aspects of business development. Funded by partners including GlaxoSmithKline and the Wellcome Trust and located just outside of London, Stevenage Bioscience Catalyst’s goal is to stimulate the growth of the U.K. life sciences sector.

“I’m looking forward to this opportunity to advise the bioincubator and its promising entrepreneurs,” says O’Donnell. “At the same time, we at RiverVest will get an early look at some potential opportunities, which we think will enhance our deal flow.”

After joining RiverVest in 2006 as a Kauffman Fellow, O’Donnell became a principal in 2010. He focuses on biopharmaceutical, diagnostic and medical device opportunities and contributes to the formation, development and business strategies of RiverVest portfolio companies.

O’Donnell earned his Ph.D. in Biochemistry from the University of Dundee, Scotland, and M.A. in Biochemistry from Pembroke College, Oxford. He also received an M.B.A. from the Rady School of Management of the University of California, San Diego.

About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is the U.K.’s first open innovation biomedical campus where companies, from start-ups to more mature firms, can benefit from proximity to the expertise and capabilities associated with a large pharmaceutical company. The joint involvement of the funding partners is designed to provide pharma and biotech companies with the opportunity to gain additional insights into a spectrum of translational research and development activities and opportunities.

By fostering a distinct culture of open innovation, Stevenage Bioscience Catalyst is creating an environment that will accelerate the pace of discovery towards product development and place the U.K. bioscience sector at the forefront of worldwide biomedical innovation, delivering cutting-edge healthcare solutions. For more information, please visit www.stevenagecatalyst.com.

About RiverVest Venture Partners®

RiverVest Venture Partners is a venture capital firm focused on identifying and shaping early-stage life science companies throughout the U.S. to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit.

Established in 2000, RiverVest has funded 29 innovative life science companies and currently has assets under management of $208 million. For more information, please visit http://www.rivervest.com.

Media Contact
Callaway Zuccarello
314-862-4300